
Sign up to save your podcasts
Or


🎙️ Real Pharma – Episode Title: Breaking the Silence: Why Pharma Needs to Speak Up
In this episode of Real Pharma, Na-Ri and Ian sit down with Brian Reid—a healthcare communicator, strategist, and former journalist who's worked across government, pharma, and media—to explore a provocative question: Why is the pharmaceutical industry so quiet when it comes to telling its own story?
Together, they unpack the communication failures shaping drug pricing, PBMs, the Inflation Reduction Act (IRA), biosimilars, and the broader healthcare system. Brian argues that the problem isn’t a lack of data or platforms—it’s a lack of courage, clarity, and commitment to narrative.
From the importance of speaking up in a noisy media environment to the myth of reputational risk, this conversation is a must-listen for anyone in life sciences, policy, or healthcare storytelling.
Why pharma’s “default to silence” is damaging public trust—and what the industry can do instead
The communications trap around complex topics like PBMs, pricing, and benefit design
How public perception problems could have been avoided with smarter storytelling (hello, Hep C)
Why simplicity is power—and how “pharm-to-table” and Mark Cuban are reframing the narrative
The case for overcommunication in the face of misinformation and AI-driven “slop”
Why the Medicare Prescription Payment Plan was a missed communication opportunity—and how to fix it
“We're in a 30-year experiment of what happens when pharma steps back from the policy debate—and the results are in.” – Brian Reid
“I just want pharma to beat Bigfoot in public trust. That’s my goal.” – Brian Reid
“When in doubt, just shout. Say something. Do something.” – Na-Ri Oh
“It’s not always about having the perfect message—it’s about showing up and making the case.” – Ian Wendt
Cost Curve – Brian Reid’s daily newsletter on healthcare policy: ReidStrategic.com
KFF’s piece on complexity as a barrier to affordability
Examples from Mark Cuban’s Cost Plus Drugs and Eli Lilly CEO Dave Ricks’ public podcast appearances
💼 Website: ReidStrategic.com
📬 Newsletter: Cost Curve
💬 LinkedIn: Brian Reid
By RealPharma5
1212 ratings
🎙️ Real Pharma – Episode Title: Breaking the Silence: Why Pharma Needs to Speak Up
In this episode of Real Pharma, Na-Ri and Ian sit down with Brian Reid—a healthcare communicator, strategist, and former journalist who's worked across government, pharma, and media—to explore a provocative question: Why is the pharmaceutical industry so quiet when it comes to telling its own story?
Together, they unpack the communication failures shaping drug pricing, PBMs, the Inflation Reduction Act (IRA), biosimilars, and the broader healthcare system. Brian argues that the problem isn’t a lack of data or platforms—it’s a lack of courage, clarity, and commitment to narrative.
From the importance of speaking up in a noisy media environment to the myth of reputational risk, this conversation is a must-listen for anyone in life sciences, policy, or healthcare storytelling.
Why pharma’s “default to silence” is damaging public trust—and what the industry can do instead
The communications trap around complex topics like PBMs, pricing, and benefit design
How public perception problems could have been avoided with smarter storytelling (hello, Hep C)
Why simplicity is power—and how “pharm-to-table” and Mark Cuban are reframing the narrative
The case for overcommunication in the face of misinformation and AI-driven “slop”
Why the Medicare Prescription Payment Plan was a missed communication opportunity—and how to fix it
“We're in a 30-year experiment of what happens when pharma steps back from the policy debate—and the results are in.” – Brian Reid
“I just want pharma to beat Bigfoot in public trust. That’s my goal.” – Brian Reid
“When in doubt, just shout. Say something. Do something.” – Na-Ri Oh
“It’s not always about having the perfect message—it’s about showing up and making the case.” – Ian Wendt
Cost Curve – Brian Reid’s daily newsletter on healthcare policy: ReidStrategic.com
KFF’s piece on complexity as a barrier to affordability
Examples from Mark Cuban’s Cost Plus Drugs and Eli Lilly CEO Dave Ricks’ public podcast appearances
💼 Website: ReidStrategic.com
📬 Newsletter: Cost Curve
💬 LinkedIn: Brian Reid

38,798 Listeners

25,905 Listeners

4,386 Listeners

170 Listeners

113,069 Listeners

1,446 Listeners

9,105 Listeners

338 Listeners

234 Listeners

6,130 Listeners

10,208 Listeners

34 Listeners

721 Listeners

58,521 Listeners

5,556 Listeners